Trials & Approvals
Leqembi Makes History as First EU-Approved Drug to Target Root Cause of Alzheimer’s Disease
2025-04-15
Bristol Myers Scores FDA Approval for Opdivo-Yervoy Combination as First-Line HCC Therapy
2025-04-14
Astrazeneca’s Calquence Combination Recommended for EU Approval in Untreated MCL Patients
2025-04-04
Biohaven’s Potential First-in-Class Autoimmune Therapy BHV-1300 Cuts Total IgG by Over 80%
2025-03-04
LATEST
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea



